These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 28884856

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [Abstract] [Full Text] [Related]

  • 23. Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease.
    Zittan E, Steinhart AH, Goldstein P, Milgrom R, Gralnek IM, Silverberg MS.
    Clin Transl Gastroenterol; 2021 Oct 06; 12(10):e00401. PubMed ID: 34613952
    [Abstract] [Full Text] [Related]

  • 24. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.
    Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, Ferrante M, Gils A, Vermeire S.
    Gut; 2016 Jul 06; 65(7):1126-31. PubMed ID: 25862647
    [Abstract] [Full Text] [Related]

  • 25. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP.
    Aliment Pharmacol Ther; 2017 Apr 06; 45(8):1135-1145. PubMed ID: 28239869
    [Abstract] [Full Text] [Related]

  • 26. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
    Paul S, Williet N, Nancey S, Veyrard P, Boschetti G, Phelip JM, Flourie B, Roblin X.
    Dig Dis Sci; 2021 Aug 06; 66(8):2744-2749. PubMed ID: 32936345
    [Abstract] [Full Text] [Related]

  • 27. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.
    Gut; 2007 Sep 06; 56(9):1232-9. PubMed ID: 17299059
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease.
    Ungar B, Ben-Shatach Z, Selinger L, Malik A, Albshesh A, Ben-Horin S, Eliakim R, Kopylov U, Carter D.
    United European Gastroenterol J; 2020 Mar 06; 8(2):167-174. PubMed ID: 32213067
    [Abstract] [Full Text] [Related]

  • 30. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
    Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA.
    Scand J Gastroenterol; 2011 Mar 06; 46(3):310-8. PubMed ID: 21087119
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis.
    Hyams JS, Dubinsky M, Rosh J, Ruemmele FM, Eichner SF, Maa JF, Lazar A, Alperovich G, Mostafa NM, Robinson AM.
    Aliment Pharmacol Ther; 2019 Jan 06; 49(2):155-164. PubMed ID: 30506693
    [Abstract] [Full Text] [Related]

  • 33. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.
    Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT.
    Clin Gastroenterol Hepatol; 2015 Jun 06; 13(6):1118-24.e3. PubMed ID: 25562796
    [Abstract] [Full Text] [Related]

  • 34. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y, Imaeda H, Nishida A, Inatomi O, Bamba S, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A.
    J Gastroenterol Hepatol; 2016 Nov 06; 31(11):1831-1836. PubMed ID: 27043158
    [Abstract] [Full Text] [Related]

  • 35. Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].
    Hisamatsu T, Matsumoto T, Watanabe K, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group .
    J Crohns Colitis; 2019 Sep 19; 13(9):1097-1104. PubMed ID: 30753377
    [Abstract] [Full Text] [Related]

  • 36. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
    Clin Gastroenterol Hepatol; 2014 Jan 19; 12(1):80-84.e2. PubMed ID: 23891927
    [Abstract] [Full Text] [Related]

  • 37. Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
    Chiu YL, Rubin DT, Vermeire S, Louis E, Robinson AM, Lomax KG, Pollack PF, Paulson SK.
    Inflamm Bowel Dis; 2013 May 19; 19(6):1112-22. PubMed ID: 23584130
    [Abstract] [Full Text] [Related]

  • 38. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
    Yarur AJ, Gondal B, Hirsch A, Christensen B, Cohen RD, Rubin DT.
    J Clin Gastroenterol; 2018 Jul 19; 52(6):537-544. PubMed ID: 28723860
    [Abstract] [Full Text] [Related]

  • 39. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov 19; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 40. Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease.
    Poon SS, Asher R, Jackson R, Kneebone A, Collins P, Probert C, Dibb M, Subramanian S.
    J Crohns Colitis; 2015 Aug 19; 9(8):640-6. PubMed ID: 25968584
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.